Mar 21, 2020
Medpace Response
6yWow! We are taken back by the accusations you’ve made in this review, specifically those made about our CEO, HR department, and the integrity of our company. To begin, Medpace is proud to be able to provide discretionary bonuses and other incentive rewards in addition to standard salary to employees who meet or exceed performance expectations. We understand it can be very disappointing not to receive a desired bonus. However, minimum eligibility and performance standards apply to all employees here at Medpace and are reviewed during this process. Our HR department prioritizes any issues brought forward by our employees. They are all reviewed and then escalated as necessary. We are always willing to address specific concerns and cannot always promise confidentiality. We make it clear that we will escalate depending on the specific concern and sometimes the nature of the concern requires some disclosure in order to resolve. We take all concerns seriously and investigate thoroughly. In regard to COVID-19, this global pandemic is new to all of us. We are navigating as best as we can and assure you we are taking this very seriously. We are complying with CDC guidelines of social distancing in the organization, extra cleaning services regularly throughout the building, and are allowing the majority of our employees to work from home 100% of the time for the next two weeks. This will be evaluated based on new information we get daily on the spread of the virus. For hourly employees who are not able to do their jobs remotely, we are ensuring they are still paid during this time even if they are unable to work their normal hours. The safety and wellbeing of our employees is our number 1 priority. As a healthcare company, we recognize the importance of the clinical trials we are currently running and the need to continue to fight all disease and continue our mission to accelerate the global development of safe and effective medical therapeutics. For our CRAs in particular this does mean continuing to monitor in ways that are safe and effective, and which allow for our clinical patients to still receive the benefits of the drugs or therapies provided to them by virtue of our studies.